Nanologica's Year-end report for 2021 will be published on Tuesday February 8, instead of January 31 as previously announced, and the company's Annual Report for 2021 will be published on Wednesday March 9, instead of April 8 as previously announced.
Dates for upcoming financial reports:
Year-end report 2021 8 February, 2022
Annual Report 2021 9 March, 2022
Interim report Jan-Mar 2022 29 April, 2022
Interim report Jan-Jun 2022 8 July, 2022
Interim report Jan-Sep 2022 28 October, 2022
Regarding the listing of Nanologica on Nasdaq Main Market, Nasdaq's listing committee intends to handle Nanologica's case in March 2022. The listing date will be announced when it is set.
For further information, please contact:
Johanna Johansson, IR, Communications and Marketing Manager
Ph: +46 72 211 21 90 or e-mail: firstname.lastname@example.org
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases. In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje and the company’s share (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.
This is a translation of the original press release that was published in Swedish.